Publications
Detailed Information
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yamaguchi, Kensei | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Iwasa, Satoru | - |
dc.contributor.author | Sugimoto, Naotoshi | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Sakai, Daisuke | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Kawakami, Hisato | - |
dc.contributor.author | Yabusaki, Hiroshi | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Shimoyama, Tatsu | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Saito, Kaku | - |
dc.contributor.author | Kawaguchi, Yoshinori | - |
dc.contributor.author | Kamio, Takahiro | - |
dc.contributor.author | Kojima, Akihito | - |
dc.contributor.author | Sugihara, Masahiro | - |
dc.contributor.author | Shitara, Kohei | - |
dc.date.accessioned | 2023-03-16T02:11:44Z | - |
dc.date.available | 2023-03-16T02:11:44Z | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.created | 2023-03-07 | - |
dc.date.issued | 2023-02 | - |
dc.identifier.citation | Journal of Clinical Oncology, Vol.41 No.4, pp.816-825 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://hdl.handle.net/10371/189392 | - |
dc.description.abstract | PURPOSE: To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS: Patients with locally advanced or metastatic HER2-low (cohort 1, immunohistochemistry 2+/in situ hybridization-negative; cohort 2, immunohistochemistry 1+) gastric/GEJ adenocarcinoma treated with at least two prior regimens, including fluoropyrimidine and platinum, but anti-HER2 therapy naive, received T-DXd 6.4 mg/kg intravenously once every 3 weeks. The primary end point was confirmed objective response rate by independent central review. RESULTS: Among 21 patients enrolled in cohort 1 and 24 enrolled in cohort 2, 19 and 21 patients, respectively, had central HER2 confirmation, received T-DXd, and had measurable tumors at baseline. The confirmed objective response rate was 26.3% (95% CI, 9.1 to 51.2) from five partial responses in cohort 1 and 9.5% (95% CI, 1.2 to 30.4) from two partial responses in cohort 2. Thirteen patients (68.4%) in cohort 1 and 12 (60.0%) in cohort 2 experienced reduced tumor size. The median overall survival was 7.8 months (95% CI, 4.7 to nonevaluable) in cohort 1 and 8.5 months (95% CI, 4.3 to 10.9) in cohort 2; the median progression-free survival was 4.4 months (95% CI, 2.7 to 7.1) and 2.8 months (95% CI, 1.5 to 4.3), respectively. The most common grade ≥ 3 treatment-emergent adverse events in cohorts 1 and 2 were anemia (30.0% and 29.2%), decreased neutrophil count (25.0% and 29.2%), and decreased appetite (20.0% and 20.8%). Drug-related interstitial lung disease/pneumonitis occurred in one patient in each cohort (grade 1 or 2). No drug-related deaths occurred. CONCLUSION: This study provides preliminary evidence that T-DXd has clinical activity in patients with heavily pretreated HER2-low gastric/GEJ adenocarcinoma. | - |
dc.language | 영어 | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.title | Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1200/JCO.22.00575 | - |
dc.citation.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.wosid | 000940780800014 | - |
dc.identifier.scopusid | 2-s2.0-85147088162 | - |
dc.citation.endpage | 825 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 816 | - |
dc.citation.volume | 41 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DRUG CONJUGATE | - |
dc.subject.keywordPlus | DS-8201A | - |
dc.subject.keywordPlus | HER2 | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TUMORS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.